» Articles » PMID: 15699230

Changes in Response to Insulin and the Effects of Varying Glucose Tolerance on Whole-body Protein Metabolism in Patients with Cystic Fibrosis

Overview
Journal Am J Clin Nutr
Publisher Elsevier
Date 2005 Feb 9
PMID 15699230
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Diabetes mellitus has been reported to increase whole-body protein breakdown and thus loss of lean body mass. Cystic fibrosis-related diabetes (CFRD) is associated with undernutrition and increased mortality.

Objective: We hypothesized that CFRD is associated with increased whole-body protein breakdown, which results in negative protein balance, and that correction of the glucose intolerance with insulin therapy would normalize whole-body protein metabolism.

Design: Rates of whole-body protein turnover and protein balance were measured in 28 adults with cystic fibrosis (17 M, 11 F). Subjects were assessed with a modified oral-glucose-tolerance test and categorized as having normal glucose tolerance, impaired glucose tolerance, or CFRD with and without fasting hyperglycemia; then they were compared with previously diagnosed CFRD adults already receiving insulin therapy. Indexes of protein turnover were calculated from [15N]glycine and 15N in urinary urea.

Results: Analysis of variance for the 28 subjects showed that whole-body protein breakdown was highest (P<0.05) in patients with CFRD. Whole-body protein synthesis was not significantly affected by impaired glucose tolerance. Significant (P<0.05) improvement in net protein synthesis occurred in the CFRD group 3 mo after insulin therapy was administered. Follow-up studies of 3 subjects with CFRD showed significant improvement in net protein synthesis after insulin therapy. Monitoring of the protein homeostasis of the impaired glucose tolerance group gave clues to the progression of their metabolic homeostasis.

Conclusion: CFRD has an adverse effect on protein homeostasis by increasing net protein synthesis.

Citing Articles

Cystic fibrosis related diabetes (CFRD) prognosis.

Sandouk Z, Khan F, Khare S, Moran A J Clin Transl Endocrinol. 2021; 26:100278.

PMID: 34926166 PMC: 8652010. DOI: 10.1016/j.jcte.2021.100278.


Associations Between Glucose Tolerance, Insulin Secretion, Muscle and Fat Mass in Cystic Fibrosis.

Nielsen B, Faurholt-Jepsen D, Oturai P, Qvist T, Krogh-Madsen R, Katzenstein T Clin Med Insights Endocrinol Diabetes. 2021; 14:11795514211038259.

PMID: 34413690 PMC: 8369959. DOI: 10.1177/11795514211038259.


Diabetes outbreak during COVID19 lock-down in a prediabetic patient with cystic fibrosis long treated with glargine.

Rosanio F, Mozzillo E, Cimbalo C, Casertano A, Sepe A, Raia V Ital J Pediatr. 2021; 47(1):121.

PMID: 34078438 PMC: 8170445. DOI: 10.1186/s13052-021-01076-7.


Peak glucose during an oral glucose tolerance test is associated with future diabetes risk in adults with cystic fibrosis.

Bonhoure A, Potter K, Colomba J, Boudreau V, Bergeron C, Desjardins K Diabetologia. 2021; 64(6):1332-1341.

PMID: 33693987 DOI: 10.1007/s00125-021-05423-5.


Drug treatments for managing cystic fibrosis-related diabetes.

Onady G, Stolfi A Cochrane Database Syst Rev. 2020; 10:CD004730.

PMID: 33075159 PMC: 8094754. DOI: 10.1002/14651858.CD004730.pub5.